We send the latest information from SMC Laboratories.
SMC announces that University of Yamanashi (Japan) has published the results of a study using STAMTM mouse model in Clinical and Experimental Gastroenterology. Title: “Changes in Function and Dynamics in Hepatic and Splenic Macrophages in Non-Alcoholic Fatty Liver Disease” In this paper, they report the involvement of liver and spleen macrophages in NASH…
SMC announces that Merck & Co., Inc. (NJ) has published the results of a study using STAMTM mouse model in Cell Reports Medicine. Title: “Molecular Profiling Reveals a Common Metabolic Signature of Tissue Fibrosis” In this paper, they report the results of pharmacology study of MK-8722 (AMPK activator) and MK-4074 (ACC inhibitor) using…
SMC announces that Sabinsa Corporation has published the results of a study using STAM model in Scientific Reports. Title: “Novel Combinatorial Regimen of Garcinol and Curcuminoids for Non-alcoholic Steatohepatitis (NASH) in Mice”
SMC announces that Continuum Biosciences, Pty Ltd. has published the results of a study using STAM model on Journal of Medicinal Chemistry (https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00542) . Title: “6-Amino-[1,2,5]oxadiazolo[3,4-b]pyrazin-5-ol Derivatives as Efficacious Mitochondrial Uncouplers in STAM Mouse Model of Non-alcoholic Steatohepatitis”
SMC announces that Juntendo University has published the results of a study using STAM™ model in European Radiology Experimental. Title: “Free fatty acid-based low-impedance liver image: a characteristic appearnace in nonalcoholic steatohepatitis (NASH)” Free fatty acid-based low-impedance liver image: a characteristic appearance in nonalcoholic steatohepatitis (NASH) | European Radiology Experimental | Full Text (springeropen.com)…
SMC announces that Genomics Institute of the Novartis Research Foundation has published the results of a study using STAM™ model in Journal of Medicinal Chemistry. Title: “Nidufexor (LMB763), a Novel FXR Modulator for the Treatment of Nonalcoholic Steatohepatitis” Nidufexor (LMB763), a Novel FXR Modulator for the Treatment of Nonalcoholic Steatohepatitis | Journal of Medicinal…
SMC announces that Can-Fite BioPharma has published the results of a study using STAM™ model in International Journal of Molecular Medicine. Title: “The A3 adenosine receptor agonist, namodenoson, ameliorates non-alcoholic steatohepatitis in mice” The A3 adenosine receptor agonist, namodenoson, ameliorates non‑alcoholic steatohepatitis in mice (spandidos-publications.com)
SMC announces that Pfizer has published the results of a study using STAM™ model in Science Translational Medicine. Title: “Targeting diacylglycerol acyltransferase 2 for the treatment of nonalcoholic steatohepatitis” Targeting diacylglycerol acyltransferase 2 for the treatment of nonalcoholic steatohepatitis | Science Translational Medicine (sciencemag.org)
SMC announces that ChemomAb has published the results of a study using STAM™ model in JHEP Reports. Title: “A Blocking Monoclonal Antibody to CCL24 Alleviates Liver Fibrosis and Inflammation in Experimental Models for Liver Damage” A blocking monoclonal antibody to CCL24 alleviates liver fibrosis and inflammation in experimental models of liver damage – ScienceDirect…
SMC announced that Genomics Institute of the Novartis Research Foundation has published the results of a study using STAM™ model on Hepatology Communications. Title: “Tropifexor-Mediated Abrogation of Steatohepatitis and Fibrosis is Associated with the Antioxidative Gene Expression Profile in Rodents”